Aprea Therapeutics, a Boston, Massachusetts- and Stockholm, Sweden-based clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, raised approx. €5m in Series C funding.
Funds managed by Janus Henderson Investors joined as a new backer, raising the total amount of the financing to €55m. Janus Henderson Investors joined the financing round closed in November, 2018, and led by Redmile Group, with participation from Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB (Nasdaq Stockholm: KDEV).
Led by Christian S. Schade, President and Chief Executive Officer, Aprea Therapeutics is a biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company’s lead drug candidate, APR-246, a first-in-class small molecule, is in clinical development for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. Aprea is also developing second generation p53 reactivators that have best-in-class potential.
The proceeds will be used to advance the clinical development of APR-246. Aprea has commenced a Phase 3 clinical study in myelodysplastic syndromes (MDS) and has completed enrollment in a Phase Ib/II clinical trial in p53 mutated high-risk myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML) with APR-246 and azacitidine.
Additional studies in MDS and AML are underway and in planning with other approved agents.